Omics-based insights into therapy failure of pediatric B-lineage acute lymphoblastic leukemia

Abstract

B-lineage acute lymphoblastic leukemia (B-ALL) is the most common type of cancer seen in children and is characterized by a variable clinical course. Although there have been remarkable improvements in the therapy outcomes of pediatric B-ALL, treatment failure remains the leading-cause of death in 18% of the afflicted patients during the first 5 years after diagnosis. Molecular heterogeneities of pediatric B-ALL play important roles as determinants of the therapy response. Therefore, many of these molecular abnormalities have an established prognostic value in the disease. The present review discusses the omics-based revelations from epigenomics, genomics, transcriptomics and proteomics about treatment failure in pediatric B-ALL. Next it highlights the promise of the molecular aberration-targeted therapy to improve the treatment outcomes.

Downloads

Download data is not yet available.
Published
2019-09-10
Section
Reviews
Keywords:
Pediatric B-ALL, therapy failure, omics.
Statistics
Abstract views: 280

PDF: 133
Share it

PlumX Metrics

PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

How to Cite
Alsagaby, S. (2019). Omics-based insights into therapy failure of pediatric B-lineage acute lymphoblastic leukemia. Oncology Reviews, 13(2). https://doi.org/10.4081/oncol.2019.435